Shao Hui Huang1, John Waldron2, Scott V Bratman3, Jie Su4, John Kim3, Andrew Bayley3, John Cho3, Meredith Giuliani3, Andrew Hope3, Jolie Ringash3, Aaron Hansen5, John R de Almeida6, David Goldstein6, Bayardo Perez-Ordonez7, Ilan Weinreb7, Li Tong3, Wei Xu4, Brian O'Sullivan2. 1. Department of Radiation Oncology, The Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. Electronic address: shaohui.huang@rmp.uhn.on.ca. 2. Department of Radiation Oncology, The Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Department of Otolaryngology-Head & Neck Surgery, The Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. 3. Department of Radiation Oncology, The Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. 4. Department of Biostatistics, The Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. 5. Division of Medical Oncology, The Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. 6. Department of Otolaryngology-Head & Neck Surgery, The Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. 7. Department of Pathology, The Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Abstract
PURPOSE: To report the outcome of ipsilateral radiation therapy (RT) in human papillomavirus (HPV)-positive (HPV+) patients and HPV-negative (HPV-) patients with T1-T2N0-N2b tonsillar cancer treated 25 years after our initial historical cohort. METHODS AND MATERIALS: Patients with T1-T2N0-N2b tonsillar cancer who received ipsilateral RT or bilateral RT between 1999 and 2014 were reviewed. Overall survival (OS), local control (LC), regional control (RC), and grade 3 to 4 late toxicity (LT) were compared between ipsilateral RT and bilateral RT within HPV+ and HPV- patients, separately. RESULTS: HPV status was ascertained in 379/427 (88%) consecutive patients (ipsilateral RT: 62 HPV+, 34 HPV-; bilateral RT: 240 HPV+ 240, 41 HPV-). The proportion of ipsilateral RT by N category for HPV+ and HPV- patients were as follows: N0: 24/37 (65%) versus 28/48 (74%); N1: 21/49 (43%) versus 4/9 (44%); N2a: 10/39 (26%) versus 1/4 (25%); and N2b: 7/177 (4%) versus 1/24 (4%), respectively. Of the patients receiving ipsilateral RT, 94/96 (98%) were treated with RT alone. The median follow-up time was 5.03 years. The respective 5-year rates of OS, LC, RC, and LT were similar between ipsilateral RT and bilateral RT for the HPV+ patients (OS: 89% vs 87%, P=.55; LC: 97% vs 98%, P=.65; RC: 98% vs 97%, P=.27; LT: 17% vs 12%, P=.83) and HPV- patients (OS: 63% vs 48%, P=.27; LC: 90% vs 80%, P=.19; RC: 94% vs 83%, P=.14; LT: 15% vs 22%, P=.36). Of the 96 patients receiving ipsilateral RT, contralateral neck failure (CNF) occurred in 1/52 HPV+ patients and 1/34 HPV- patients. The 5-year CNF rates were 2% (95% CI: 1-9) (HPV+: 2% [0-14]; HPV-: 3% [0-21], P=.66). Five local failures (2 HPV+; 3 HPV-) and no distant failures were seen. The 5-year rates of LC, RC, and LT were 97% versus 90% (P=.24), 98% versus 94% (P=.25), and 18% versus 15% (P=.75) for the HPV+ and HPV- cohorts, respectively. Osteoradionecrosis occurred in 9 patients: 6/47 (13%) treated with conventional RT and 3/49 (6%) with intensity modulated RT (P=.32). CONCLUSION: Ipsilateral radiation to selected patients with T1-T2N0-N2b tonsillar cancer results in equally excellent outcomes regardless of tumor HPV status.
PURPOSE: To report the outcome of ipsilateral radiation therapy (RT) in human papillomavirus (HPV)-positive (HPV+) patients and HPV-negative (HPV-) patients with T1-T2N0-N2b tonsillar cancer treated 25 years after our initial historical cohort. METHODS AND MATERIALS: Patients with T1-T2N0-N2b tonsillar cancer who received ipsilateral RT or bilateral RT between 1999 and 2014 were reviewed. Overall survival (OS), local control (LC), regional control (RC), and grade 3 to 4 late toxicity (LT) were compared between ipsilateral RT and bilateral RT within HPV+ and HPV- patients, separately. RESULTS: HPV status was ascertained in 379/427 (88%) consecutive patients (ipsilateral RT: 62 HPV+, 34 HPV-; bilateral RT: 240 HPV+ 240, 41 HPV-). The proportion of ipsilateral RT by N category for HPV+ and HPV- patients were as follows: N0: 24/37 (65%) versus 28/48 (74%); N1: 21/49 (43%) versus 4/9 (44%); N2a: 10/39 (26%) versus 1/4 (25%); and N2b: 7/177 (4%) versus 1/24 (4%), respectively. Of the patients receiving ipsilateral RT, 94/96 (98%) were treated with RT alone. The median follow-up time was 5.03 years. The respective 5-year rates of OS, LC, RC, and LT were similar between ipsilateral RT and bilateral RT for the HPV+ patients (OS: 89% vs 87%, P=.55; LC: 97% vs 98%, P=.65; RC: 98% vs 97%, P=.27; LT: 17% vs 12%, P=.83) and HPV- patients (OS: 63% vs 48%, P=.27; LC: 90% vs 80%, P=.19; RC: 94% vs 83%, P=.14; LT: 15% vs 22%, P=.36). Of the 96 patients receiving ipsilateral RT, contralateral neck failure (CNF) occurred in 1/52 HPV+ patients and 1/34 HPV- patients. The 5-year CNF rates were 2% (95% CI: 1-9) (HPV+: 2% [0-14]; HPV-: 3% [0-21], P=.66). Five local failures (2 HPV+; 3 HPV-) and no distant failures were seen. The 5-year rates of LC, RC, and LT were 97% versus 90% (P=.24), 98% versus 94% (P=.25), and 18% versus 15% (P=.75) for the HPV+ and HPV- cohorts, respectively. Osteoradionecrosis occurred in 9 patients: 6/47 (13%) treated with conventional RT and 3/49 (6%) with intensity modulated RT (P=.32). CONCLUSION: Ipsilateral radiation to selected patients with T1-T2N0-N2b tonsillar cancer results in equally excellent outcomes regardless of tumor HPV status.
Authors: Nicolette Taku; Gregory Chronowski; G Brandon Gunn; William H Morrison; Neil D Gross; Amy C Moreno; Renata Ferrarotto; Steven J Frank; C David Fuller; Ryan P Goepfert; Jack Phan; Stephen Y Lai; Jay P Reddy; David I Rosenthal; Adam S Garden Journal: Int J Radiat Oncol Biol Phys Date: 2022-05-02 Impact factor: 8.013
Authors: C Jillian Tsai; Thomas J Galloway; Danielle N Margalit; Richard L Bakst; Beth M Beadle; Jonathan J Beitler; Steven Chang; Allen Chen; Jay Cooper; Shlomo A Koyfman; John A Ridge; Jared Robbins; Minh Tam Truong; Sue S Yom; Farzan Siddiqui Journal: Head Neck Date: 2020-10-17 Impact factor: 3.821
Authors: Olgun Elicin; Paul Martin Putora; Marco Siano; Martina A Broglie; Christian Simon; Daniel Zwahlen; Gerhard F Huber; Giorgio Ballerini; Lorenza Beffa; Roland Giger; Sacha Rothschild; Sandro V Negri; Pavel Dulguerov; Guido Henke Journal: Front Oncol Date: 2019-10-24 Impact factor: 6.244
Authors: Axel Sahovaler; John J W Lee; Wei Xu; Susie Su; Ali Hosni; Andrew Bayley; David P Goldstein; John R de Almeida Journal: J Otolaryngol Head Neck Surg Date: 2021-12-23
Authors: Robert H Press; Richard L Bakst; Sonam Sharma; Rafi Kabarriti; Madhur K Garg; Brian Yeh; Daphna Y Gelbum; Shaakir Hasan; J Isabelle Choi; Chris A Barker; Arpit M Chhabra; Charles B Simone; Nancy Y Lee Journal: Int J Part Ther Date: 2021-06-25